Ajanta Pharma Board Approves Sub Division of Shares

MUMBAI, India - Jan. 28, 2015 - PRLog -- Ajanta Pharma Board Approves Sub Division of Shares

Nominal value to be subdivided from Rs. 5/- per share to Rs. 2/- per share

Mumbai, 28^th January 2015:  Ajanta Pharma Limited,a specialty focused pharmaceutical formulation company announced that its Board of Directors, in their meeting held on 28^th January 2015 approved sub-division of nominal value of equity shares of the Company from Rs. 5/- each to nominal value of Rs. 2/- each and consequential amendment to the Memorandum of Association and Articles of Association, subject to approval of Members of the Company to be taken by postal ballot.

With the proposed sub division, number of shares of the company will increase from 3,51,77,400 of Rs. 5/- each to 8,79,43,500 of Rs. 2/- each. The total paid up share capital of the company will remain at Rs. 17.58 cr.

About Ajanta Pharma Limited

Ajanta Pharma - a speciality pharmaceutical formulation company has a well-established branded generic business in India and emerging markets.  It has leading brands in therapeutic segments of Ophthalmology, Dermatology, Cardiology and Pain management in India.  In emerging markets, Company has customised product basket with wider therapeutics presence.  Many of company’s products are first in the market place and are leading in their sub therapeutic segments.

The company is now building a portfolio of ANDAs for the regulated markets of USA and has recently entered this market with its maiden product.

Company’s state of the art R&D centre for formulation development is located at Mumbai, having a team of 350+ people.  Company has world class manufacturing facilities - 4 located in India and 1 at Mauritius.  One of the manufacturing facilities in India is approved by US FDA, UK MHRA, pre-qualification from WHO, apart from having approval from FDAs of many other countries.  Company is setting up two more manufacturing facilities in India, one for regulated markets and another for domestic/emerging markets.

For last 5 years, company has posted healthy performance with its consolidated revenue showing a CAGR of 31% and net profit of 62%.

For specific queries, contact:

Gaurang Shah Tel: +91 22 66061204

Email:gaurang.shah@ajantapharma.com